Literature DB >> 15257377

[Multiple sclerosis: potential therapeutic options and update of ongoing studies].

H Wiendl1, H C Lehmann, R Hohlfeld, H-P Hartung, B C Kieseier.   

Abstract

The therapeutic options for the treatment of multiple sclerosis (MS) have experienced enormous progress over recent years. Despite these encouraging developments, available therapies are only partially effective, and the ultimate goal of curing MS is still far from being attained. The improved understanding of the cellular and molecular mechanisms of MS (immune) pathogenesis together with recent shifts in paradigms led to a variety of new therapeutic targets and approaches. In addition to modulation of the inflammatory process, therapeutic approaches focussing on active neuroprotection, remyelinization, and regeneration have become increasingly important. Based on current concepts of the MS pathogenesis, this article summarizes new therapeutic approaches. Substances and strategies currently tested in clinical trials are reviewed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15257377     DOI: 10.1007/s00115-003-1665-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  134 in total

1.  Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker.

Authors:  D Krametter; G Niederwieser; A Berghold; G Birnbaum; S Strasser-Fuchs; H P Hartung; J J Archelos
Journal:  Mult Scler       Date:  2001-02       Impact factor: 6.312

2.  Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors:  Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal:  Science       Date:  2002-03-28       Impact factor: 47.728

3.  How promising is hematopoetic stem cell transplantation in multiple sclerosis?

Authors:  Reinhard Hohlfeld
Journal:  J Neurol       Date:  2002-09       Impact factor: 4.849

4.  Growth factor treatment of demyelinating disease: at last, a leap into the light.

Authors:  Richard M Ransohoff; Charles L Howe; Moses Rodriguez
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

5.  Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions.

Authors:  A Maeda; R A Sobel
Journal:  J Neuropathol Exp Neurol       Date:  1996-03       Impact factor: 3.685

6.  BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

Authors:  Christine Stadelmann; Martin Kerschensteiner; Thomas Misgeld; Wolfgang Brück; Reinhard Hohlfeld; Hans Lassmann
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

7.  A functional and structural basis for TCR cross-reactivity in multiple sclerosis.

Authors:  Heather L E Lang; Helle Jacobsen; Shinji Ikemizu; Christina Andersson; Karl Harlos; Lars Madsen; Peter Hjorth; Leif Sondergaard; Arne Svejgaard; Kai Wucherpfennig; David I Stuart; John I Bell; E Yvonne Jones; Lars Fugger
Journal:  Nat Immunol       Date:  2002-09-03       Impact factor: 25.606

8.  Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial.

Authors:  A A Vandenbark; Y K Chou; R Whitham; M Mass; A Buenafe; D Liefeld; D Kavanagh; S Cooper; G A Hashim; H Offner
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

Review 9.  Remyelination in multiple sclerosis.

Authors:  Wolfgang Brück; Tanja Kuhlmann; Christine Stadelmann
Journal:  J Neurol Sci       Date:  2003-02-15       Impact factor: 3.181

10.  Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system.

Authors:  P Villoslada; S L Hauser; I Bartke; J Unger; N Heald; D Rosenberg; S W Cheung; W C Mobley; S Fisher; C P Genain
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.